Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Reclassification from AOCI, Current Period, before Tax, Attributable to Parent

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's reclassification from aoci, current period, before tax, attributable to parent.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's reclassification from AOCI, current period, before tax, attributable to parent?
BioMarin Pharmaceuticals (BMRN) reported reclassification from AOCI, current period, before tax, attributable to parent of -$8.81M in Q1 2026.
How has BioMarin Pharmaceuticals's reclassification from AOCI, current period, before tax, attributable to parent changed year-over-year?
BioMarin Pharmaceuticals's reclassification from AOCI, current period, before tax, attributable to parent decreased by 188.7% year-over-year, from $9.94M to -$8.81M.